Consensus Castle Biosciences, Inc.

Stocks

CSTL

US14843C1053

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-08-26 EDT			5-day change	1st Jan Change
34.08 ^USD	-2.63%		+17.40%	-12.39%

08-17	Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas	MT
07-31	Castle Biosciences, Inc., Q2 2026 Earnings Call, Jul 30, 2026

Evolution of the Average Target: Castle Biosciences, Inc.

Evolution of the Target Price: Castle Biosciences, Inc.

Changes in Analyst Recommendations: Castle Biosciences, Inc.

0cf9ae8dc8e94ebd5382422e3c.OenOoBSMkbw9oBtFmBZXJ2J1sF1AhLpuizmiC5Z1HoE.fLz6xSbbyddR-HgtqGF6czER9jl07PQA01XwTqIbKrJYtvnMXtrSynPQbA~fc67c1506669a9b819afdc2017c18ceb

Analysts' recommendations: Castle Biosciences, Inc.

06-25	Roth Capital Initiates Castle Biosciences at Buy	MT
23-12-14	Guggenheim Initiates Castle Biosciences With Buy Rating, $25 Price Target	MT
23-08-04	KeyBanc Adjusts Price Target on Castle Biosciences to $25 From $37, Maintains Overweight Rating	MT
23-06-15	BTIG Research Adjusts Castle Biosciences Price Target to $30 From $38, Maintains Buy Rating	MT
23-06-06	Scotiabank Adjusts Castle Biosciences Price Target to $33 From $54, Maintains Sector Outperform Rating	MT
23-06-06	Canaccord Genuity Adjusts Price Target on Castle Biosciences to $40 From $60, Keeps Buy Rating	MT
23-06-05	SVB Securities Adjusts Price Target on Castle Biosciences to $35 From $50, Maintains Outperform Rating	MT
23-06-05	Lake Street Adjusts Castle Biosciences' Price Target to $32 From $41, Keeps Buy Rating	MT
23-06-05	Baird Adjusts Castle Biosciences Price Target to $25 From $35, Maintains Outperform Rating	MT
23-05-05	KeyBanc Adjusts Price Target on Castle Biosciences to $37 From $40, Maintains Overweight Rating	MT
23-05-04	Baird Adjusts Price Target on Castle Biosciences to $35 From $38, Maintains Outperform Rating	MT
23-03-01	Baird Adjusts Price Target on Castle Biosciences to $38 From $42, Maintains Outperform Rating	MT
23-01-05	Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target	MT
22-11-03	Baird Adjusts Castle Biosciences' Price Target to $41 From $48, Keeps Outperform Rating	MT
22-08-09	SVB Securities Adjusts Castle Biosciences' Price Target to $50 from $45, Keeps Market Outperform Rating	MT
22-08-09	Baird Adjusts Castle Biosciences' Price Target to $48 From $44, Maintains Outperform Rating	MT
22-05-11	KeyBanc Adjusts Castle Biosciences' Price Target to $40 from $90, Keeps Overweight Rating	MT
22-05-10	SVB Securities Adjusts Castle Biosciences' Price Target to $45 from $65, Keeps Outperform Rating	MT
22-05-10	Baird Adjusts Price Target on Castle Biosciences to $44 From $50, Keeps Outperform Rating	MT
22-04-05	Canaccord Genuity Adjusts Castle Biosciences Price Target to $80 From $94, Maintains Buy Rating	MT
22-01-07	Stephens Initiates Castle Biosciences With Overweight Rating, $59 Price Target	MT
22-01-07	Stephens Starts Castle Biosciences at Overweight With $59 Price Target	MT
21-11-09	SVB Leerink Adjusts Price Target on Castle Biosciences to $75 From $85, Maintains Outperform Rating	MT
21-11-09	Baird Adjusts Price Target on Castle Biosciences to $82 From $78, Keeps Outperform Rating	MT
21-08-10	Castle Biosciences : Baird Adjusts Castle Biosciences PT to $78 From $73, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CASTLE BIOSCIENCES, INC.					+25.71%
	GUARDANT HEALTH, INC.					+17.81%
	BIOMÉRIEUX					+4.69%
	10X GENOMICS, INC.					-23.46%
	CARIS LIFE SCIENCES, INC.					-3.61%
	LANTHEUS HOLDINGS, INC.					+6.12%
	SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.					+28.51%
	DIASORIN S.P.A.					-5.66%
	AUTOBIO DIAGNOSTICS CO., LTD.					+14.26%
	Average					+7.15%
	Weighted average by Cap.					+6.76%